MIRA INFORM REPORT
|
Report No. : |
323374 |
|
Report Date : |
08.06.2015 |
IDENTIFICATION DETAILS
|
Name : |
SINOPHARM WEIQIDA DATONG PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
Second Medical Zone, Economy & Technological Development Zone, Datong, Shanxi Province 037300 Pr |
|
|
|
|
Country : |
China |
|
|
|
|
Financials (as on) : |
31.12.2014 |
|
|
|
|
Date of Incorporation : |
20.09.2001 |
|
|
|
|
Com. Reg. No.: |
140200400001682 |
|
|
|
|
Legal Form : |
Chinese-Foreign Equity Joint Venture Enterprise |
|
|
|
|
Line of Business : |
Subject is engaged in manufacturing and selling antibiotics. |
|
|
|
|
No of Employees : |
1,400 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderate Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderate High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
CHINA ECONOMIC OVERVIEW
Since the late 1970s China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role - in 2010 China became the world's largest exporter. Reforms began with the phasing out of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, growth of the private sector, development of stock markets and a modern banking system, and opening to foreign trade and investment. China has implemented reforms in a gradualist fashion. In recent years, China has renewed its support for state-owned enterprises in sectors considered important to "economic security," explicitly looking to foster globally competitive industries. After keeping its currency tightly linked to the US dollar for years, in July 2005 China moved to an exchange rate system that references a basket of currencies. From mid 2005 to late 2008 cumulative appreciation of the renminbi against the US dollar was more than 20%, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing allowed resumption of a gradual appreciation. In 2014 the People’s Bank of China (PBOC) doubled the daily trading band within which the RMB is permitted to fluctuate. The restructuring of the economy and resulting efficiency gains have contributed to a more than tenfold increase in GDP since 1978. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2014 stood as the largest economy in the world, surpassing the US that year... Still, per capita income is below the world average.
The Chinese government faces numerous economic challenges, including: (a) reducing its high domestic savings rate and correspondingly low domestic consumption; (b) facilitating higher-wage job opportunities for the aspiring middle class, including rural migrants and increasing numbers of college graduates; (c) reducing corruption and other economic crimes; and (d) containing environmental damage and social strife related to the economy's rapid transformation. Economic development has progressed further in coastal provinces than in the interior, and by 2014 more than 274 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of population control policy is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and economic development. The Chinese government is seeking to add energy production capacity from sources other than coal and oil, focusing on nuclear and alternative energy development.
|
Source
: CIA |
Company
name & address
SINOPHARM WEIQIDA
DATONG PHARMACEUTICAL CO., LTD.
SECOND MEDICAL ZONE,
ECONOMY & TECHNOLOGICAL DEVELOPMENT ZONE, DATONG, SHANXI PROVINCE 037300 PR
CHINA
TEL: 86 (0)
352-7698888*8816
FAX: 86 (0)
352-7695555
EXECUTIVE
SUMMARY
Date of Registration : september 20, 2001
REGISTRATION NO. : 140200400001682
LEGAL FORM : Chinese-foreign equity joint venture
enterprise
REGISTERED CAPITAL : CNY 467,975,272
staff :
1,400
BUSINESS CATEGORY : MANUFACTURING
& TRADING
Revenue :
CNY 1,459,450,000 (AS OF DEC. 31, 2014)
EQUITIES :
CNY 370,140,000 (AS OF DEC. 31, 2014)
WEBSITE : N/A
E-MAIL :
N/A
PAYMENT :
AVERAGE
MARKET CONDITION : COMPETITIVE
FINANCIAL CONDITION : fairLY STABLE
OPERATIONAL TREND : FAIRLY STEADY
GENERAL REPUTATION : AVERAGE
EXCHANGE RATE :
CNY 6.20 = USD 1
Adopted
abbreviations (as follows)
SC - Subject Company
(the company inquired by you)
N/A – Not available
CNY – China Yuan Ren
Min Bi
OPERATIONAL
TREND & GENERAL REPUTATION
This section aims at indicating the relative positions of SC in respect
of its operational trend & general reputation
Operational Trend:- General
Reputation:-
Upward Excellent
Steady Good
Fairly Steady Fairly
Good
Ordinary Average
Fair Fair
Stagnant Detrimental
Downward Not
known
Not known Not
yet be determined
Not yet be determined
LEGAL
STATUS & HISTORY
SC was established
as a Chinese-foreign equity joint venture enterprise of PRC with State
Administration of Industry & Commerce (SAIC) under registration No.: 140200400001682 on September 20, 2001.
SC’s Organization Code Certificate No.:
73189319-9
SC’s Tax No.: 140216731893199
SC’s Customs Registration No.: 1402930106
SC’s registered capital: CNY 467,975,272
SC’s paid-in capital: CNY 467,975,272
Registration Change Record:-
No significant changes of SC have been noted
in SAIC since its incorporation.
Current Co search indicates SC’s shareholders & chief executives are
as follows:-
|
Name of Shareholder (s) |
% of Shareholding |
|
Skysen International Holding Limited
(B.V.I.) |
13.5 |
|
Aurobindo Pharma Ltd. (India) |
19.5 |
|
Sinopharm Weiqida Pharmaceutical Co. Ltd. |
67 |
SC’s Chief Executives:-
|
Position |
Name |
|
Legal Representative and Chairman |
Han Yanlin |
|
Director |
Guo Yimin |
|
Li Xianlin |
|
|
Hu Zhihong |
|
|
Arvind chandak |
|
|
Li Hao |
|
|
Zhu Shengtao |
|
|
Supervisor |
Yu Xiang |
|
Yan Liping |
|
|
Chen Danya |
RECENT
DEVELOPMENT
No recent development was found during our checks at present.
SHAREHOLDER
CHART & BACKGROUND
Name %
of Shareholding
Skysen International Holding Limited
(B.V.I.) 13.5
Aurobindo Pharma Ltd. (India) 19.5
Sinopharm Weiqida Pharmaceutical Co. Ltd. 67
Sinopharm Weiqida
Pharmaceutical Co. Ltd.
-----------------------------------------------------------
Registration No.: 140200400001754
Registered Capital: CNY 593,939,394
MANAGEMENT
Han Yanlin, Legal Representative and Chairman
--------------------------------------------------------------------------
Ø
Gender: M
Ø Qualification:
University
Ø Working experience
(s):
At present, working in SC as legal
representative and chairman, also working in Sinopharm Weiqida Pharmaceutical
Co. Ltd. as vice chairman
Director
----------
Guo Yimin (Also working in Sinopharm Weiqida
Pharmaceutical Co. Ltd. as legal representative)
Li Xianlin
Hu Zhihong
Arvind chandak
Li Hao
Zhu Shengtao
Supervisor
--------------
Yu Xiang
Yan Liping
Chen Danya
BUSINESS
OPERATION
SC’s registered business scope includes manufacturing and
selling API; purchasing grain; manufacturing and selling starch sugar and
organic fertilizer; rental plant and equipment, develop new products; providing
after-sale service.
SC is mainly
engaged in manufacturing and selling antibiotics.
SC’s products mainly
include: amoxicillin, etc.
SC sources its materials 90% from domestic market, mainly Shanxi, and 10% from overseas market. SC sells 40% of its products in domestic market, and 60% to overseas market, mainly U.S.A., India, etc.
The buying terms
of SC include Check, T/T, L/C and Credit of 30-60 days. The payment terms of SC
include T/T, L/C and Credit of 30-60 days.
*Major Customers*
----------------------
Fersinsa Gb, S.A.
De C.V.
Teva
Pharmaceuticals USA Inc.
Staff & Office:
--------------------------
SC is known
to have approx. 1,400 staff
at present.
SC owns an area as
its operating office and factory, but the detailed information is unknown.
RELATED
COMPANY
SC
is not known to have any subsidiary at present.
PAYMENT
Overall payment appraisal:
( ) Excellent ( ) Good (X) Average ( ) Fair ( ) Poor ( ) Not yet be determined
The appraisal serves as a reference to reveal SC's payments habits and
ability to pay. It is based on the 3
weighed factors: Trade payment experience (through current enquiry with SC's
suppliers), our delinquent payment and our debt collection record concerning
SC.
Trade payment experience: SC did not
provide any name of trade/service suppliers and we have no other sources to conduct
the enquiry at present.
Delinquent payment record: None in our
database.
Debt collection record: No overdue amount
owed by SC was placed to us for collection within the last 6 years.
BANKING
The bank
information of SC is not filed in SAIC.
FINANCIALS
Financial Summary
|
Unit: CNY’000 |
As
of Dec. 31, 2014 |
|
Total assets |
2,402,560 |
|
|
------------- |
|
Total
liabilities |
2,032,420 |
|
Equities |
370,140 |
|
|
------------- |
|
Revenue |
1,459,450 |
|
Profit before
tax |
72,120 |
|
Less: profit tax |
0 |
|
Profits |
72,120 |
Important Ratios
=============
|
|
As
of Dec. 31, 2014 |
|
*Liabilities
to assets |
0.85 |
|
*Net profit
margin (%) |
4.94 |
|
*Return on
total assets (%) |
3.00 |
|
*Revenue/Total
assets |
0.61 |
FINANCIAL
COMMENTS
PROFITABILITY:
AVERAGE
l The revenue of SC
appears fairly good in its line.
l SC’s net profit
margin is average.
l SC’s return on
total assets is average.
LIQUIDITY: FAIR
l
SC’s revenue is in a fair level, comparing with the
size of its total assets.
LEVERAGE: AVERAGE
l
The debt ratio of SC is average.
l
The risk for SC to go bankrupt is average.
Overall financial
condition of the SC: Fairly Stable.
CONCLUSIONS
SC is considered large-sized in its line with fairly stable financial
conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs. 63.89 |
|
|
1 |
Rs. 97.97 |
|
Euro |
1 |
Rs. 71.81 |
INFORMATION DETAILS
|
Analysis Done by
: |
KRN |
|
|
|
|
Report Prepared
by : |
DPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall
operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.